

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME

This voluntary announcement is made by MedSci Healthcare Holdings Limited (the “**Company**”).

Reference is made to the announcement of the Company dated 19 September 2023 (the “**Announcement**”) in relation to the adoption of the share award scheme (the “**Scheme**”) by the Company. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

On 25 June 2024, the Trustee purchased a total of 100,000 Shares on the Stock Exchange for the purpose of the Scheme. Details of the purchase are as follow:

Date of purchase:	25 June 2024
Total number of Shares purchased:	100,000 Shares (representing approximately 0.02% of the total number of Shares in issue as at the date of purchase)
Average consideration per Share:	Approximately HK\$1.87
Total consideration of Shares purchased (excluding transaction costs):	Approximately HK\$0.2 million
Balance of Shares held by the Trustee immediately after the purchase:	123,295 Shares

According to the Scheme, the Board may, from time to time, at its sole and absolute discretion select any Eligible Participant (other than any Excluded Participant) for participation in the Scheme as a Selected Participant, and grant an Award to any Selected Participant at such consideration (if any) subject to such terms and conditions as the Board may in its sole and absolute discretion determine.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司
Dr. Zhang Fabao

Chairman of the Board and Executive Director

Hong Kong, 26 June 2024

As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Fan Jie and Mr. Wang Shuai, as executive Directors; Mr. Hu Xubo and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.